Ligand Pharmaceuticals Bets Big on Royalty Growth

Ligand Pharmaceuticals Inc ((LGND)) has held its Q1 earnings call. Read on for the main highlights of the call.

Ligand Pharmaceuticals’ latest earnings call struck an optimistic tone as management detailed strong royalty growth, expanding earnings power and a transformative acquisition pipeline. While they acknowledged GAAP volatility and timing risks around partner-dependent revenues and the pending XOMA deal, executives argued that diversified royalties and upcoming catalysts should drive durable value creation for shareholders.

Royalty Revenue Acceleration

Royalties surged to $43.0 million in the first quarter of 2026, a 56% year-over-year increase that underpinned the bullish narrative on the call. Management credited the growth to momentum from key partnered drugs Filspari, Ohtuvayre and Qarziba, highlighting royalties as the core engine of the company’s model.

Total Revenue and Adjusted EPS Growth

Total revenue climbed 14% year over year to $52.0 million, illustrating that the top line is growing even with some lumpy components. Adjusted diluted EPS rose 23% to $1.63, underscoring improving profitability from the royalty platform despite ongoing non-cash noise in reported GAAP earnings.

XOMA Royalty Acquisition — Scale and Near-Term Accretion

The centerpiece of Ligand’s strategy update was the announced acquisition of XOMA Royalty, expected to close in the third quarter of 2026 and materially expand the portfolio. The deal adds more than 120 assets, including seven marketed products, nearly doubles Phase II and III programs and is projected to boost adjusted EPS by about $0.50 in 2026 and $1.50 in 2027.

Major Clinical and Regulatory Catalysts

On the pipeline front, Palvella’s QTORIN rapamycin posted positive Phase III SELVA data with a 2.13-point gain on the primary endpoint, comfortably beating internal expectations and paving the way for an NDA in the second half of 2026. In parallel, Travere’s Filspari secured full FDA approval for FSGS, broadening its label and setting up a larger royalty opportunity for Ligand.

Large Peak Opportunity Signals for Key Assets

Executives leaned into the long-term upside by framing potential peak sales for their most important partnered programs. They cited Filspari’s combined IgAN and FSGS opportunity at roughly $3.0 billion in peak sales, implying around $270 million in annual royalties, and pegged QTORIN rapamycin’s U.S. peak at $1.0 billion to $3.0 billion, suggesting $100 million to $300 million in potential royalty income.

Improved Operating Efficiency and Scale

Since pivoting to a royalty aggregation model, Ligand has aggressively slimmed down and refocused its operations, reducing headcount from about 200 employees to roughly 40 and cutting operating expenses from about $90 million to about $40 million. At the same time, the company expanded its deal team to 18, more than doubled commercial assets from seven to 15 and closed 18 transactions in three years, signaling a lean but scaled platform.

Strong Liquidity Position

The call highlighted a robust balance sheet, with about $780 million in cash and investments at quarter end and an undrawn $200 million revolver providing nearly $1.0 billion of available capital. Management emphasized that this war chest gives Ligand ample flexibility to fund the XOMA acquisition and pursue additional royalty deals without stressing the balance sheet.

Fair Value Volatility and Elevated Nonoperating Expense

Despite solid underlying results, nonoperating expense spiked to $41.6 million in the quarter, up from $14.0 million a year ago due largely to fair-value swings in equity holdings such as Pelthos. The company underscored that this factor creates meaningful GAAP volatility that can obscure the trajectory of core royalty earnings from quarter to quarter.

GAAP Loss Despite Adjusted Profitability

Ligand reported a GAAP diluted loss per share of $0.67, an improvement from a $2.21 loss a year earlier but still in the red on a reported basis due to mark-to-market and other non-cash items. Management argued that adjusted profitability, fueled by rising recurring royalties, offers a clearer picture of the business than headline GAAP results.

Captisol and Contract Revenue Lumpiness

Captisol revenue provided a reminder that not every revenue stream is trending up, as sales declined year over year and remained inherently lumpy by quarter. Even so, the company reiterated full-year Captisol guidance of $35 million to $40 million and cautioned that contract revenue will similarly ebb and flow depending on partner milestones and timing.

Dependence on Partner Execution and Timing Risks

The call repeatedly stressed that Ligand’s fortunes are tied to the execution of its partners, from launch pacing and reimbursement to regional approvals and milestone schedules. Recent examples included modest headwinds for Ohtuvayre from seasonality and reimbursement timing and the Filspari approval landing later than initially expected, both contributing to revenue timing uncertainty.

Pending XOMA Transaction and Uncertain Upside

While bullish on XOMA’s strategic logic, management acknowledged that the transaction remains pending and carries some unknowns. In particular, upside linked to a litigation-contingent CVR and the magnitude of XOMA’s tax attributes remains uncertain until closing, leaving investors with some open questions on the ultimate financial benefit.

Guidance and Multi-Year Outlook

Ligand reaffirmed its 2026 outlook assuming the XOMA deal closes in the third quarter, guiding to $270 million to $310 million in total revenue, $225 million to $250 million in royalty revenue and adjusted EPS of $8.50 to $9.50. The company expects roughly $300 million of operating cash flow in 2027, with plans to deploy $150 million to $250 million per year into new royalty opportunities while XOMA is projected to contribute $0.50 to adjusted EPS in 2026 and $1.50 in 2027.

Ligand’s earnings call painted the picture of a lean royalty aggregator with accelerating royalty income, a sizable acquisition in motion and a growing slate of high-value partnered assets. While GAAP noise, partner-dependent timing and the still-pending XOMA close inject some uncertainty, management’s confidence in sustained royalty growth and disciplined capital deployment will likely keep the stock firmly on investors’ watchlists.